Global melanoma market set to reach $3.6 billion by 2020
The global melanoma therapeutics market was valued at $1.3 billion in 2013 and will expand at a compound annual growth rate (CAGR) of 15.4% to reach $3.6 billion by 2020, according to new research findings.
The latest report from business intelligence provider GBI Research states that the majority of this impressive increase, which relates to eight major countries (the USA, Canada, Germany, France, Italy, Spain, the UK and Japan), will occur in the USA, where the market value will rise from around $1 billion in 2013 to $2.6 billion by the end of the forecast period.
Fiona Chisholm, an analyst for GBI Research, states that the prolific growth anticipated in the USA is primarily attributable to the increasing prevalence of cutaneous melanoma, rising treatment rates and the expanded uptake of recently approved and emerging premium drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze